Am J Transplant, Volume 19, Suppl 3 Archives - Page 161 of 214 - ATC Abstracts

2019 American Transplant Congress
Changes in Kidney Offer Acceptance for Pediatric Candidates Post-KAS
M. Bowring, K. Jackson, J. Garonzik-Wang, D. Segev, A. Massie
Johns Hopkins University, Baltimore, MD
*Purpose:Stakeholders have expressed concerns regarding kidney transplant rates for pediatric candidates under KAS. To better understand what might be driving potential declines in access, we…
2019 American Transplant Congress
Anti-HLA IgM Antibodies Are Reduced in Highly-HLA Sensitized Patients Transplanted after Imlifidase (IdeS) Treatment
X. Zhang¹, S. Jordan²
¹HLA and Immunogenetics Laboratory, Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA
*Purpose: Immunoglobulin-degrading enzyme from Streptococcus pyogenes (IdeS, Imlifidase) has been used to reduce antibody levels to promote transplant of highly sensitized patients. In vitro experiments…
2019 American Transplant Congress
Molecular Analysis of Rejection and Injury in Human Liver Transplant Biopsies: First Results of the INTERLIVER Study
P. F. Halloran and The INTERLIVER Study Group
University of Alberta, Edmonton AB, AB, Canada
*Purpose: The relationship of histologic liver transplant biopsy assessments to actual rejection and injury is unclear. Recent progress in molecular reclassification of kidney, heart, and…
2019 American Transplant Congress
MHC Molecule-Ablated Human Endothelial Cells Form Alloimmune-Evasive Microvessels
J. Merola¹, M. Reschke², L. Qin¹, S. Spindler¹, R. W. Pierce³, T. D. Manes⁴, G. Li¹, L. Bracaglia², N. Kirkiles-Smith⁴, T. Baltazar⁴, W. Saltzman², G. T. Tietjen¹, G. Tellides¹, J. S. Pober⁴
¹Surgery, Yale School of Medicine, New Haven, CT, ²Biomedical Engineering, Yale School of Engineering and Applied Science, New Haven, CT, ³Pediatrics, Yale School of Medicine, New Haven, CT, ⁴Immunobiology, Yale School of Medicine, New Haven, CT
*Purpose: “Off the shelf” tissue-engineered organs will require use of allogeneic cell sources. Allogeneic human endothelial cells (ECs), necessary for organ perfusion, can initiate graft…
2019 American Transplant Congress
Senescent Cell Clearance with Senolytic Drugs Improves Cardiac Allograft Survival by Targeting mt-DNA Mediated Immune Responses
J. Iske¹, M. Koichiro¹, M. Seyda¹, T. Heinbokel¹, Y. Nian¹, R. Maenosono¹, H. Azuma¹, C. Falk², T. Tchokonia³, J. Kirkland³, A. Elkhal¹, S. Tullius¹
¹Transplant Surgery, Brigham and Women's Hospital, Boston, MA, ²Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, ³Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN
*Purpose: Older organs represent an underutilized potential. We dissected alloimmune responses when transplanting older organs and tested if the depletion of senescent cells in older…
2019 American Transplant Congress
More Than Meets the Eye: The Use of Serial Intravascular Ultrasound for Assessment of Cardiac Allograft Vasculopathy after Heart Transplantation
Y. Moayedi¹, C. Fan², M. Tremblay-Gravel¹, R. J. Miller¹, M. Kawana¹, J. Parizo¹, G. Oro¹, R. Wainwright¹, H. I. Luikart¹, N. D'Emilio¹, J. Gordon¹, R. Kameda¹, M. Ikutomi¹, C. Manlhiot¹, W. F. Fearon¹, H. J. Ross¹, K. K. Khush¹, J. J. Teuteberg¹
¹Stanford University, Palo Alto, CA, ²University of Toronto, Toronto, ON, Canada
*Purpose: Cardiac allograft vasculopathy (CAV) is the “Achilles heel” of long-term survival after heart transplantation. While conventional coronary angiography is recognised as the standard for…
2019 American Transplant Congress
Prevention of Ischemia Reperfusion Injury (IRI) & ABMR in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH): Long-Term Follow Up
A. A. Vo, E. Huang, N. Ammerman, J. Choi, I. Kim, A. Peng, R. Najjar, S. Sethi, K. Lim, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Delayed graft function (DGF) after kidney transplantation is a consequence of IRI/DGF. IRI/DGF requires intense medical management, is costly and predisposes to risk for…
2019 American Transplant Congress
Risk Factors for Recurrence and Predictors of Response in Kidney Transplant Recipients with Primary FSGS
A. Uffing¹, T. TANGO-consortium², P. Cravedi³, L. V. Riella¹
¹Renal Division, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²NA, Boston, MA, ³Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: Primary focal segmental glomerulosclerosis (FSGS) is a glomerular disease that frequently recurs after kidney transplantation. Several circulating factors have been proposed to cause recurrence…
2019 American Transplant Congress
Continuous Distribution: LSAM Simulation Study
T. Weaver¹, N. Salkowski¹, J. Snyder¹, D. Schladt¹, J. Pyke¹, A. Herreid¹, B. Thompson¹, W. Kim², J. Lake³, A. Israni¹
¹SRTR, Minneapolis, MN, ²Stanford Univ, Stanford, CA, ³Univ of Minnesota, Minneapolis, MN
*Purpose: This liver simulated allocation model (LSAM) study of a simple continuous distribution system for several parameter values introduces and describes its characteristics, demonstrating how…
2019 American Transplant Congress
Mismatched Epitope and De Novo DSA Development: An Analysis of the Benefit and Benefit-EXT Renal Transplant Cohorts
V. Jucaud¹, V. Burnett¹, H. Gebel², R. Bray², M. Polinsky³, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Emory University, Atlanta, GA, ³Bristol-Myers Squibb, Princeton, NJ
*Purpose: De novo donor-specific HLA antibodies (dnDSA) target epitopes rather than whole antigens, and their development is associated with the mismatched HLA antibody epitope load…